{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T19:00:01Z","timestamp":1777143601542,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001026","name":"National Breast Cancer Foundation","doi-asserted-by":"publisher","award":["PF-17-007"],"award-info":[{"award-number":["PF-17-007"]}],"id":[{"id":"10.13039\/501100001026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001026","name":"National Breast Cancer Foundation","doi-asserted-by":"publisher","award":["RSP-155-18\/19"],"award-info":[{"award-number":["RSP-155-18\/19"]}],"id":[{"id":"10.13039\/501100001026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2005294"],"award-info":[{"award-number":["APP2005294"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000950","name":"Cancer Council South Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.breast.2021.04.003","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T04:22:21Z","timestamp":1618978941000},"page":"57-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3262-5374","authenticated-orcid":false,"given":"Natansh D.","family":"Modi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4182-065X","authenticated-orcid":false,"given":"Ahmad Y.","family":"Abuhelwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6404-4649","authenticated-orcid":false,"given":"Sarah","family":"Badaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7651-9851","authenticated-orcid":false,"given":"Emily","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiran","family":"Shankaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3725-793X","authenticated-orcid":false,"given":"Ross A.","family":"McKinnon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Sorich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley M.","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2021.04.003_bib1","first-page":"203","article-title":"Clinical potential of novel therapeutic targets in breast cancer: CDK4\/6, Src, JAK\/STAT, PARP, HDAC, and PI3K\/AKT\/mTOR pathways","volume":"7","author":"Hosford","year":"2014","journal-title":"Pharmgenomics Pers Med"},{"key":"10.1016\/j.breast.2021.04.003_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3892\/br.2013.187","article-title":"Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review)","volume":"2","author":"Zhang","year":"2014","journal-title":"Biomed Rep"},{"key":"10.1016\/j.breast.2021.04.003_bib3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2147\/DDDT.S137783","article-title":"Abemaciclib: a CDK4\/6 inhibitor for the treatment of HR+\/HER2- advanced breast cancer","volume":"12","author":"Corona","year":"2018","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.breast.2021.04.003_bib4","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.breast.2021.04.003_bib5","author":"Nsw"},{"key":"10.1016\/j.breast.2021.04.003_bib6","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000499534","article-title":"Management of adverse events due to cyclin-dependent kinase 4\/6 inhibitors","volume":"14","author":"Ettl","year":"2019","journal-title":"Breast Care"},{"key":"10.1016\/j.breast.2021.04.003_bib7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor\u2013positive, ERBB2-negative breast cancer that progressed on endocrine therapy\u2014MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2021.04.003_bib8","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","article-title":"MONARCH 1, A phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)\/HER2(-) metastatic breast cancer","volume":"23","author":"Dickler","year":"2017","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.breast.2021.04.003_bib9","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2021.04.003_bib10","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2021.04.003_bib11","author":"Company"},{"key":"10.1016\/j.breast.2021.04.003_bib12","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1080\/14740338.2020.1781814","article-title":"Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor","volume":"19","author":"Gebbia","year":"2020","journal-title":"Expet Opin Drug Saf"},{"key":"10.1016\/j.breast.2021.04.003_bib13","first-page":"218","article-title":"Predictive and prognostic models: implications for healthcare decision-making in a modern recession","volume":"2","author":"Vogenberg","year":"2009","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.breast.2021.04.003_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-014-0241-z","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement","volume":"13","author":"Collins","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.breast.2021.04.003_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"npj Breast Canc"},{"key":"10.1016\/j.breast.2021.04.003_bib16","first-page":"5938","volume":"17","author":"Bischl","year":"2016","journal-title":"mlr: Mach Learn R."},{"key":"10.1016\/j.breast.2021.04.003_bib17","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1002\/onco.13531","article-title":"Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3","volume":"26","author":"Rugo","year":"2021","journal-title":"Oncol"},{"key":"10.1016\/j.breast.2021.04.003_bib18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.7861\/clinmedicine.13-2-185","article-title":"Neutropenic sepsis: management and complications","volume":"13","author":"Clarke","year":"2013","journal-title":"Clin Med"},{"key":"10.1016\/j.breast.2021.04.003_bib19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ygyno.2012.03.015","article-title":"Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer","volume":"125","author":"Laskey","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.breast.2021.04.003_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.6587","article-title":"Ethnic neutropenia among women of European, African, and Caribbean backgrounds","volume":"25","author":"Grann","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2021.04.003_bib21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000366466","article-title":"Management of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropenia","volume":"9","author":"Fontanella","year":"2014","journal-title":"Breast Care"},{"key":"10.1016\/j.breast.2021.04.003_bib22","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00280-020-04051-x","article-title":"Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer","volume":"85","author":"Keum","year":"2020","journal-title":"Canc Chemother Pharmacol"},{"key":"10.1016\/j.breast.2021.04.003_bib23","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","article-title":"Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review","volume":"90","author":"Lyman","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.breast.2021.04.003_bib24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/psp4.12544","article-title":"Development and application of a mechanistic population modeling approach to describe abemaciclib pharmacokinetics","volume":"9","author":"Chigutsa","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.breast.2021.04.003_bib25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10549-018-5054-x","article-title":"The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4\/6 inhibitors in advanced breast cancer: a meta-analysis","volume":"174","author":"Lee","year":"2019","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.breast.2021.04.003_bib26","first-page":"233","article-title":"What do cancer patients worry about when making decisions about treatment? Variation across racial\/ethnic groups","volume":"22","author":"Martin","year":"2014","journal-title":"Support Care Canc"},{"key":"10.1016\/j.breast.2021.04.003_bib27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/2042098617722516","article-title":"Gastrointestinal adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: a systematic review and meta-analysis","volume":"8","author":"Shohdy","year":"2017","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.breast.2021.04.003_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918793326","article-title":"Management of adverse events during cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor-based treatment in breast cancer","volume":"10","author":"Thill","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.breast.2021.04.003_bib29","doi-asserted-by":"crossref","first-page":"iv126","DOI":"10.1093\/annonc\/mdy145","article-title":"Diarrhoea in adult cancer patients: ESMO clinical practice guidelines","volume":"29","author":"Bossi","year":"2018","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.breast.2021.04.003_bib30","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s40266-015-0318-1","article-title":"Age-related changes in hepatic function: an update on implications for drug therapy","volume":"32","author":"Tan","year":"2015","journal-title":"Drugs Aging"},{"key":"10.1016\/j.breast.2021.04.003_bib31","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/1060028018795146","article-title":"Abemaciclib: the newest CDK4\/6 inhibitor for the treatment of breast cancer","volume":"53","author":"Palumbo","year":"2018","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.breast.2021.04.003_bib32","doi-asserted-by":"crossref","first-page":"373","DOI":"10.5694\/mja13.00172","article-title":"Polypharmacy among inpatients aged 70 years or older in Australia","volume":"202","author":"Hubbard","year":"2015","journal-title":"Med J Aust"},{"key":"10.1016\/j.breast.2021.04.003_bib33","doi-asserted-by":"crossref","DOI":"10.1186\/s12871-016-0265-3","article-title":"Randomized controlled trials vs. observational studies: why not just live together?","volume":"16","author":"Faraoni","year":"2016","journal-title":"BMC Anesthesiol"},{"key":"10.1016\/j.breast.2021.04.003_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024537","article-title":"Analysis and reporting of adverse events in randomised controlled trials: a review","volume":"9","author":"Phillips","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.breast.2021.04.003_bib35","doi-asserted-by":"crossref","first-page":"102908","DOI":"10.1016\/j.critrevonc.2020.102908","article-title":"A\u00a0literature review of treatment-specific clinical prediction models in patients with breast cancer","volume":"148","author":"Modi","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.breast.2021.04.003_bib36","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1078-0432.CCR-19-1425","article-title":"Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR(+)\/HER2(-) breast cancer","volume":"26","author":"Hurvitz","year":"2020","journal-title":"Clin Canc Res"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977621003556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977621003556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:43:17Z","timestamp":1760776997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977621003556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":36,"alternative-id":["S0960977621003556"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2021.04.003","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2021.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}